Organization
PeproMene Bio
2 clinical trials
1 abstract
Clinical trial
A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-cell Acute Lymphoblastic LeukemiaStatus: Recruiting, Estimated PCD: 2026-11-18
Clinical trial
A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)Status: Recruiting, Estimated PCD: 2027-07-13
Abstract
PMB-CT01 (BAFFR-CAR T cell) therapy to examine preliminary safety and clinical responses in patients with B-cell malignancies who are ineligible for or failed CD19-directed therapy, including CD19-negative disease.Org: City of Hope National Medical Center, PeproMene Bio,